KALVISTA PHARMA Revenue, Profits - KALV Annual Income Statement

Add to My Stocks
$17.05 $0.12 (0.7%) KALV stock closing price Sep 17, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the KALVISTA PHARMA stock price. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. Like any other income statement, the KALV income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue decline of -29.58% when compared to the same period in the past. Along with KALVISTA PHARMA assets and KALVISTA PHARMA free cash flow, KALVISTA PHARMA profits as shown in profit and loss statement give key insights about the business. The net profit for 2017 is $-18.6M and the 2017 revenue is $1.5M.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is May - Apr20172016201520142013
KALVISTA PHARMA Revenues or Net Sales
Cost Of Goods Sold (COGS)-----
Research & Development Expense12.66M14.66M8.28M4.22M1.95M
Selling General & Admin Expense11.17M2.65M1.6M1.4M1.41M
Income Before Depreciation Depletion Amortization-22.33M-15.18M-8.08M-5.21M-1.83M
Depreciation Depletion Amortization-----
Non Operating Income3.73M3.74M--0.05M-
Interest Expense-----
Provision for Income Taxes-----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-18.6M-11.43M-7.22M-5.67M-2.05M
Extraordinary Items & Discontinued Operations-----
KALVISTA PHARMA Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS4.65M1.36M---
Average Shares used to compute Basic EPS4.65M1.36M---
Income Before Nonrecurring Items-18.6M-24.85M---
Income from Nonrecurring Items-----
KALVISTA PHARMA Earnings Per Share Basic Net
KALVISTA PHARMA Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-4.47-18.21---
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Durect financial analysis

KALVISTA PHARMA stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that KALV stock has a topline or revenue of $1.5M for 2017 as per this KALVISTA PHARMA revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: Most businesses like KALVISTA PHARMA try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the KALV income statement, one can check the KALVISTA PHARMA historical stock prices to check how the price has moved with time.

KALVISTA PHARMA Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield

Annual Income Statements - KALVISTA PHARMA Industry Peers

ALLERGY THERAPT income statement, Durect income statement, Zynex income statement